Patents by Inventor Morris Mosseri

Morris Mosseri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060178293
    Abstract: A polypeptide which has a positive inotropic effect on cultured cardiomyocytes and is non-toxic to mammals. The polypeptide may be isolated from Buthinae scorpion venom. Also disclosed is a pharmaceutical composition comprising the polypeptide and a DNA molecule encoding the polypeptide.
    Type: Application
    Filed: May 19, 2004
    Publication date: August 10, 2006
    Inventors: Eliahu Zlotkin, Morris Mosseri
  • Patent number: 6190302
    Abstract: A method and apparatus for dynaimic stereotactic radiotreatment and prevention of restenosis. A stent is implanted in a coronary artery, following percutaneous transluminal coronary angioplasty. Subsequent restenosis is minimized by external irradiation of the stent by ionizing radiation such as gamma rays. The fact that the stent is significantly more opaque to x-rays than the surrounding tissue is exploited to track the stent using fluoroscopy, so that the ionizing radiation can be aimed accurately at the stent. Preferably, the fluoroscopic imaging and the irradiation of the stent are synchronized with the patient's cardiac cycle. The external irradiation may be performed hours or days after implanting the stent, for prevention of restenosis, or weeks or months after implanting the stent, for treatment of restenosis, and may be fractionated.
    Type: Grant
    Filed: November 18, 1998
    Date of Patent: February 20, 2001
    Assignee: Hadasit Medical Research Services and Development Company Ltd.
    Inventors: Morris Mosseri, Zeev Weshler
  • Patent number: 6093141
    Abstract: A method and apparatus for dynamic stereotactic radiotreatment and prevention of restenosis. A stent is implanted in a coronary artery, following percutaneous transluminal coronary angioplasty. Subsequent restenosis is minimized by external irradiation of the stent by ionizing radiation such as gamma rays. The fact that the stent is significantly more opaque to x-rays than the surrounding tissue is exploited to track the stent using fluoroscopy, so that the ionizing radiation can be aimed accurately at the stent. Preferably, the fluoroscopic imaging and the irradiation of the stent are synchronized with the patient's cardiac cycle. The external irradiation may be performed hours or days after implanting the stent, for prevention of restenosis, or weeks or months after implanting the stent, for treatment of restenosis, and may be fractionated.
    Type: Grant
    Filed: July 17, 1997
    Date of Patent: July 25, 2000
    Assignee: Hadasit Medical Research and Development Company Ltd.
    Inventors: Morris Mosseri, Zeev Weshler